Levi Mangarin

2.1k total citations · 1 hit paper
15 papers, 515 citations indexed

About

Levi Mangarin is a scholar working on Immunology, Oncology and Cancer Research. According to data from OpenAlex, Levi Mangarin has authored 15 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Levi Mangarin's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Levi Mangarin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Levi Mangarin collaborates with scholars based in United States. Levi Mangarin's co-authors include Taha Merghoub, Jedd D. Wolchok, Cailian Liu, Dmitriy Zamarin, Roberta Zappasodi, Sadna Budhu, Alfredo Castro, Jill Cavanaugh, Stephane Pourpe and Ivan Cohen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Levi Mangarin

14 papers receiving 507 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

2020 335 citations Luís Felipe Campesato, Sadna Budhu et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Levi Mangarin United States	5	220	181	163	105	94	15	515
Stephen Searles United States	11	117 0.5×	70 0.4×	180 1.1×	37 0.4×	11 0.1×	16	499
Lydia Raines United States	9	182 0.8×	53 0.3×	221 1.4×	52 0.5×	10 0.1×	16	472
Shannon K. Oda United States	9	213 1.0×	131 0.7×	180 1.1×	76 0.7×	11 0.1×	17	431
Amal Mansour Egypt	11	60 0.3×	49 0.3×	126 0.8×	22 0.2×	25 0.3×	23	315
Alessia Capone Italy	10	206 0.9×	100 0.6×	115 0.7×	24 0.2×	9 0.1×	23	413
Junnian Zheng China	10	180 0.8×	116 0.6×	110 0.7×	53 0.5×	5 0.1×	12	371
Narumi Suzuki Japan	6	132 0.6×	73 0.4×	150 0.9×	39 0.4×	7 0.1×	13	399
Yuefei Yu United States	14	236 1.1×	120 0.7×	266 1.6×	30 0.3×	4 0.0×	29	476
Vinh Dao United States	9	135 0.6×	137 0.8×	142 0.9×	17 0.2×	5 0.1×	15	346
Ruth Seelige United States	11	193 0.9×	58 0.3×	154 0.9×	13 0.1×	9 0.1×	16	384

Countries citing papers authored by Levi Mangarin

Since Specialization

Citations

This map shows the geographic impact of Levi Mangarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Levi Mangarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Levi Mangarin more than expected).

Fields of papers citing papers by Levi Mangarin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Levi Mangarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Levi Mangarin. The network helps show where Levi Mangarin may publish in the future.

Co-authorship network of co-authors of Levi Mangarin

This figure shows the co-authorship network connecting the top 25 collaborators of Levi Mangarin. A scholar is included among the top collaborators of Levi Mangarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Levi Mangarin. Levi Mangarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Dong, Lauren, Hyejin Choi, Sadna Budhu, et al.. (2024). Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models. Cancer Immunology Research. 12(10). 1392–1408. 4 indexed citations

Weng, Chien‐Huan, Shabnam Eghbali, Sébastien Monette, et al.. (2024). Abstract 7472: Melanoma-intrinsic expression of signal-regulatory protein alpha (SIRPα) confers tumor cells resistance to anti-tumor adaptive immunity. Cancer Research. 84(6_Supplement). 7472–7472. 1 indexed citations

Verma, Svena, Sadna Budhu, Inna Serganova, et al.. (2024). Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. Journal of Clinical Investigation. 134(17). 30 indexed citations

Verma, Svena, Roberta Zappasodi, Sadna Budhu, et al.. (2023). 1444 Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade. SHILAP Revista de lepidopterología. A1607–A1607. 1 indexed citations

Mangarin, Levi, Stephen Martis, Sara Schad, et al.. (2023). 968 PD-1^hiFoxp3^-CD4⁺ tumor-infiltrating T-cell lineage commitment impacts the immunotherapy outcome. SHILAP Revista de lepidopterología. A1075–A1075. 1 indexed citations

Kraehenbuehl, Lukas, Aliya Holland, Levi Mangarin, et al.. (2022). Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers. 14(11). 2638–2638. 15 indexed citations

Verma, Svena, Inna Serganova, Sadna Budhu, et al.. (2022). Abstract 3537: Pharmacologic inhibition of the glycolytic pathway improves response to immune checkpoint blockade. Cancer Research. 82(12_Supplement). 3537–3537. 1 indexed citations

Verma, Svena, Inna Serganova, Sadna Budhu, et al.. (2022). 904 LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression. Regular and Young Investigator Award Abstracts. A942–A942. 1 indexed citations

Verma, Svena, Rachana Maniyar, Myat Ko, et al.. (2021). 619 Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy. SHILAP Revista de lepidopterología. A649–A649. 2 indexed citations

10.

Hirschhorn, Daniel, Allison Betof Warner, Rachana Maniyar, et al.. (2021). Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight. 6(20). 5 indexed citations

11.

Campesato, Luís Felipe, Sadna Budhu, Jeremy H. Tchaicha, et al.. (2020). Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications. 11(1). 4011–4011. 335 indexed citations breakdown →

12.

Mangarin, Levi, Cailian Liu, Roberta Zappasodi, et al.. (2020). 493 Tired and hungry: a potential role for CD47 in T cell exhaustion. SHILAP Revista de lepidopterología. A304.2–A305. 3 indexed citations

13.

Ricca, Jacob, Anton Oseledchyk, Tyler Walther, et al.. (2018). Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy. 26(4). 1008–1019. 111 indexed citations

14.

Ricca, Jacob, Anton Oseledchyk, Levi Mangarin, et al.. (2018). Pre-Existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. SSRN Electronic Journal. 1 indexed citations

15.

Hirschhorn, Daniel, Jacob Ricca, Billel Gasmi, et al.. (2018). A delicate interplay between adaptive and innate immunity caused by immunotherapy triggers tumor immunity and aseptic inflammation. The Journal of Immunology. 200(Supplement_1). 178.42–178.42. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact